Confusion over thiazolidinedione-induced heart failure: need for a better definition of heart failure

References

• Erdmann E, Wilcox RG. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. Eur. Heart J.29(1), 12–20 (2008).
   PubMed Web of Science ®Google Scholar
• Haffner SM, D’Agostino R Jr, Mykkanen L et al. Insulin sensitivity in subjects with Type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care22(4), 562–568 (1999).
   PubMed Web of Science ®Google Scholar
• Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol. Rev.75(3), 473–486 (1995).
   PubMed Web of Science ®Google Scholar
• Reaven G. Syndrome X. Curr. Treat. Options Cardiovasc. Med.3(4), 323–332 (2001).
   PubMedGoogle Scholar
• Ajjan RA, Grant PJ. Cardiovascular disease and insulin resistance. Cardiovascular Medicine, Third Edition. Willerson JT, Cohn JN, Wellens HJJ, Holmes DR (Eds). Springer–Verlag Ltd, London, UK, 2803–2818 (2007).
   Google Scholar
• Yki-Jarvinen H. Thiazolidinediones. N. Engl. J. Med.351(11), 1106–1118 (2004).
   PubMed Web of Science ®Google Scholar
• Bailey CJ. Treating insulin resistance in Type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes. Metab.7(6), 675–691 (2005).
   PubMed Web of Science ®Google Scholar
• Ajjan RA, Grant PJ. Cardiovascular disease prevention in patients with Type 2 diabetes: the role of oral anti-diabetic agents. Diab. Vasc. Dis. Res.3(3), 147–158 (2006).
   PubMedGoogle Scholar
• Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet366(9493), 1279–1289 (2005).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med.356(24), 2457–2471 (2007).
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis. N. Engl. J. Med.357(1), 28–38 (2007).
   PubMed Web of Science ®Google Scholar
• Xiang AH, Peters RK, Kjos SL et al. Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes55(2), 517–522 (2006).
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Yusuf S, Bosch J et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet368(9541), 1096–1105 (2006).
   PubMed Web of Science ®Google Scholar
• Li C, Ford ES, McGuire LC, Mokdad AH. Association of metabolic syndrome and insulin resistance with congestive heart failure: findings from the Third National Health and Nutrition Examination Survey. J. Epidemiol. Community Health61(1), 67–73 (2007).
   PubMed Web of Science ®Google Scholar
• Paolisso G, De RS, Marrazzo G et al. Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. Metabolism40, 972–977 (1991).
   PubMed Web of Science ®Google Scholar
• Amato L, Paolisso G, Cacciatore F et al. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. Diabetes Metab.23(3), 213–218 (1997).
   PubMed Web of Science ®Google Scholar
• Paolisso G, Tagliamonte MR, Rizzo MR et al. Prognostic importance of insulin-mediated glucose uptake in aged patients with congestive heart failure secondary to mitral and/or aortic valve disease. Am. J. Cardiol.83, 1338–1344 (1999).
   PubMed Web of Science ®Google Scholar
• Doehner W, Rauchhaus M, Ponikowski P et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J. Am. Coll. Cardiol.46(6), 1019–1026 (2005).
   PubMed Web of Science ®Google Scholar
• Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation111(5), 583–590 (2005).
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H. The PROactive study: some answers, many questions. Lancet366(9493), 1241–1242 (2005).
   PubMed Web of Science ®Google Scholar
• Witteles RM, Tang WH, Jamali AH, Chu JW, Reaven GM, Fowler MB. Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link. J. Am. Coll. Cardiol.44(1), 78–81 (2004).
   PubMed Web of Science ®Google Scholar
• Swan JW, Anker SD, Walton C et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J. Am. Coll. Cardiol.30(2), 527–532 (1997).
   PubMed Web of Science ®Google Scholar
• Erdmann E, Charbonnel B, Wilcox RG et al.; PROactive investigators. Pioglitazone use and heart failure in patients with Type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive X07). Diabetes Care30, 2773–2778 (2007).
   PubMed Web of Science ®Google Scholar
• Coronel R, de Groot JR, van Lieshout JJ. Defining heart failure. Cardiovasc. Res.50, 419–422 (2001).
   PubMed Web of Science ®Google Scholar
• Tan LB, Al-Timman JK, Marshall P, Cooke GA. Heart failure: can it be defined? Eur. J. Clin. Pharm.49(Suppl. 1), S11–S18 (1996).
   Google Scholar
• Cotter G, Williams SG, Vered Z, Tan LB. Role of cardiac power in heart failure. Curr. Opin. Cardiol.18(3), 215–222 (2003).
   PubMed Web of Science ®Google Scholar
• Nicholls DP, Riley MS. Measuring cardiac power output – the acid test. Eur. Heart J.22(16), 1368–1370 (2001).
   PubMed Web of Science ®Google Scholar
• Williams SG, Barker D, Goldspink DF, Tan LB. A reappraisal of concepts in heart failure: central role of cardiac power reserve. Arch. Med. Sci.1, 65–74 (2005).
   Google Scholar
• Rennings AJ, Smits P, Stewart MW, Tack CJ. Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects. Diabetes Care29(3), 581–587 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T. Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention. Proc. Natl Acad. Sci. USA102(26), 9406–9411 (2005).
   PubMed Web of Science ®Google Scholar